StockNews.com Begins Coverage on Chimerix (NASDAQ:CMRX)

Analysts at StockNews.com began coverage on shares of Chimerix (NASDAQ:CMRX) in a research report issued on Wednesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

CMRX has been the topic of a number of other reports. HC Wainwright restated a “neutral” rating and set a $8.55 price target (down from $11.00) on shares of Chimerix in a research note on Wednesday, March 5th. Wedbush reissued a “neutral” rating and set a $8.55 target price (up previously from $7.00) on shares of Chimerix in a research note on Wednesday, March 5th. Finally, Jefferies Financial Group restated a “hold” rating and set a $8.50 target price (down from $10.00) on shares of Chimerix in a report on Wednesday, March 5th.

Chimerix Trading Down 0.1 %

NASDAQ CMRX opened at $8.54 on Wednesday. The stock has a fifty day simple moving average of $7.31 and a 200-day simple moving average of $3.92. The stock has a market cap of $801.09 million, a PE ratio of -9.09 and a beta of -0.17. Chimerix has a twelve month low of $0.75 and a twelve month high of $8.55.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. The company had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.31 million. Research analysts predict that Chimerix will post -0.99 EPS for the current year.

Insider Transactions at Chimerix

In other news, CEO Michael T. Andriole sold 7,370 shares of Chimerix stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the transaction, the chief executive officer now owns 609,603 shares in the company, valued at approximately $2,755,405.56. This trade represents a 1.19 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders have sold 20,760 shares of company stock valued at $91,175. 13.10% of the stock is currently owned by company insiders.

Institutional Trading of Chimerix

A number of large investors have recently made changes to their positions in CMRX. Squarepoint Ops LLC acquired a new position in Chimerix during the 4th quarter worth approximately $130,000. Two Sigma Investments LP grew its stake in shares of Chimerix by 309.1% during the fourth quarter. Two Sigma Investments LP now owns 101,156 shares of the biopharmaceutical company’s stock worth $352,000 after purchasing an additional 76,430 shares in the last quarter. OMERS ADMINISTRATION Corp purchased a new position in Chimerix in the fourth quarter valued at $535,000. Millennium Management LLC raised its stake in Chimerix by 6.8% in the fourth quarter. Millennium Management LLC now owns 2,557,530 shares of the biopharmaceutical company’s stock valued at $8,900,000 after buying an additional 161,795 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C acquired a new stake in Chimerix in the fourth quarter valued at $13,124,000. 45.42% of the stock is currently owned by hedge funds and other institutional investors.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.